Differences between Two Real-Time PCR-Based Hepatitis C Virus (HCV) Assays (RealTime HCV and Cobas AmpliPrep/Cobas TaqMan) and One Signal Amplification Assay (Versant HCV RNA 3.0) for RNA Detection and Quantification
about
KASL clinical practice guidelines: management of hepatitis CUpdate on hepatitis B and C virus diagnosisA Novel Diagnostic Target in the Hepatitis C Virus GenomeAbbott RealTime Hepatitis C Virus (HCV) and Roche Cobas AmpliPrep/Cobas TaqMan HCV Assays for Prediction of Sustained Virological Response to Pegylated Interferon and Ribavirin in Chronic Hepatitis C PatientsEvaluation of the Abbott Investigational Use Only RealTime Hepatitis C Virus (HCV) Assay and Comparison to the Roche TaqMan HCV Analyte-Specific Reagent AssayClinical Laboratory Testing in the Era of Directly Acting Antiviral Therapies for Hepatitis CFuture microfluidic and nanofluidic modular platforms for nucleic acid liquid biopsy in precision medicine.Real-time PCR assays for hepatitis B virus DNA quantification may require two different targets.A novel duplex real-time reverse transcriptase-polymerase chain reaction assay for the detection of hepatitis C viral RNA with armored RNA as internal control.Development of a new duplex real-time polymerase chain reaction assay for hepatitis B viral DNA detection.Development of a second version of the Cobas AmpliPrep/Cobas TaqMan hepatitis C virus quantitative test with improved genotype inclusivity.Evidence-based consensus on the diagnosis, prevention and management of hepatitis C virus disease.Molecular diagnostics in the management of chronic hepatitis C: key considerations in the era of new antiviral therapies.Molecular methods and platforms for infectious diseases testing a review of FDA-approved and cleared assays.Performance of two HCV RNA assays during protease inhibitor-based triple therapy in patients with advanced liver fibrosis and cirrhosis.Real-Time PCR Assays for the Quantification of HCV RNA: Concordance, Discrepancies and Implications for Response Guided Therapy.Japanese reference panel of blood specimens for evaluation of hepatitis C virus RNA and core antigen quantitative assaysA case-control study of factors associated with resolution of hepatitis C viremia in former blood donors (CME)SASLT practice guidelines: management of hepatitis C virus infection.Predicting factors of present hepatitis C virus infection among patients positive for the hepatitis C virus antibody.Methods for Preparation of MS2 Phage-Like Particles and Their Utilization as Process Control Viruses in RT-PCR and qRT-PCR Detection of RNA Viruses From Food Matrices and Clinical Specimens.The COBAS ® TaqMan ® hepatitis C virus assays: automated systems for accurate and sensitive viral load quantification.Applicability of Hepatitis C Virus RNA Viral Load Thresholds for 8-Week Treatments in Patients With Chronic Hepatitis C Virus Genotype 1 Infection.Profile of Roche's cobas® HCV tests.European Multicenter Study on Analytical Performance of DxN Veris System HCV AssayMulticenter Comparison Study of both Analytical and Clinical Performance across Four Roche Hepatitis C Virus RNA Assays Utilizing Different Platforms.An OPTIMIZE study retrospective analysis for management of telaprevir-treated hepatitis C virus (HCV)-infected patients by use of the Abbott RealTime HCV RNA assay.Introduction of an automated system for the diagnosis and quantification of hepatitis B and hepatitis C viruses.Performance of the Abbott RealTime and Roche Cobas TaqMan hepatitis C virus (HCV) assays for quantification of HCV genotypes.Variation analysis of six HCV viral load assays using low viremic HCV samples in the range of the clinical decision points for HCV protease inhibitors.Comparison of two quantitative real-time CMV-PCR tests calibrated against the 1st WHO international standard for viral load monitoring of renal transplant patients.Post-transfusion-transmitted hepatitis C virus infection: a study on thalassemia and hemodialysis patients in southeastern Iran.Alterations in immune function are associated with liver enzyme elevation in HIV and HCV co-infection after commencement of combination antiretroviral therapy.The future of viral hepatitis testing: innovations in testing technologies and approaches.Screening HCV genotype-specific epitope peptides based on conserved sequence analysis and B cell epitope prediction in HCV E2 region.KASL clinical practice guidelines: management of hepatitis C.
P2860
Q26752471-40DC8431-1CD3-4C2C-B841-FFEF7D22303DQ26777048-7E25AC90-1C39-44D0-8BCA-CFB8BD17814FQ27487878-81C4D0DD-C5DB-4289-921C-BD0D357CF5B0Q27487942-9704ACC2-A9FF-4E15-8283-C3661DB4D03EQ27489512-1A3F4A9D-263B-4F7C-99FE-5CA49634BEF3Q28080225-7518B39C-92D7-44FD-A356-C14022A3B273Q30357091-9570B5BE-D92C-4D90-B8B4-81AB56A8F82BQ33667860-0EDBB8BA-15FA-4BFD-8A2F-57D7BEF9ED18Q33991980-5C48899E-FF7A-425E-B2C9-E69AD58B174AQ35049431-1A1E8567-F8D4-4BD6-BCD6-3A0330C50FA7Q35192311-1D17201D-16E6-48F5-8E7B-432544AFBED1Q35237341-74973B14-7688-4067-AF7E-43805E931689Q35263756-CCFD31A6-B3F6-467C-AB31-7C10C08A5FB4Q35356381-18C0EA04-07E8-4735-8839-C03B70D602F7Q35412591-E30CDEE0-6F24-4096-A5BA-163F283443CAQ35746376-976CE321-29D8-49C1-A581-BB93947B1240Q36022842-FC5B9F4D-F182-43BA-BC7A-DC3E54DCC66BQ36863802-A06ABA46-A99F-4B6D-84FE-AAC5E5F3BC30Q37019765-F0C73336-2C38-4EA8-92DA-00B90FCCE4B8Q37488818-9597A6CB-411A-4EB3-AA8D-2F0013261E3CQ38364815-3D65284A-C688-4F46-86A5-D2568FCD732DQ39694201-0ED2C054-8554-4BB2-8D80-9F7FDD928294Q39973981-B34C209E-8A0F-4330-96B1-53AD0A4334DFQ40300359-83FDC36F-9E85-4D63-9290-F2F9464E652EQ40348977-5721A39A-FEE6-46BD-9E34-5CC25DC18C35Q40358244-C576FD57-CD4C-43DA-92D9-3C3B22180965Q41476752-FF45C2B2-CB8D-4E47-AB08-BA989506227BQ41809253-CEAD0EFE-0BB1-464A-B367-5BE8F518630EQ42143350-372F27DD-A5EE-457A-8F8D-85492FBAA1D2Q42181383-A78E7681-948F-4AF3-8D9A-AB94840B9B79Q42270373-9EB2F8BA-03C3-4AAC-8C6F-19F3D3D9D61BQ43034552-377A6417-B107-4DC1-831B-D60E12D32837Q43040666-E65DA72D-79C3-442D-83FC-2BD6B41BB6E1Q47107841-E0214BAC-CD2B-49D0-8355-B872A632198CQ47335897-CE517A94-824D-450A-9D26-AFC48B1B17E5Q51836024-17B4BE15-7347-4AE1-926D-62B44AAA7A95
P2860
Differences between Two Real-Time PCR-Based Hepatitis C Virus (HCV) Assays (RealTime HCV and Cobas AmpliPrep/Cobas TaqMan) and One Signal Amplification Assay (Versant HCV RNA 3.0) for RNA Detection and Quantification
description
2008 nî lūn-bûn
@nan
2008 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Differences between Two Real-T ...... A Detection and Quantification
@ast
Differences between Two Real-T ...... A Detection and Quantification
@en
Differences between Two Real-T ...... A Detection and Quantification
@nl
type
label
Differences between Two Real-T ...... A Detection and Quantification
@ast
Differences between Two Real-T ...... A Detection and Quantification
@en
Differences between Two Real-T ...... A Detection and Quantification
@nl
prefLabel
Differences between Two Real-T ...... A Detection and Quantification
@ast
Differences between Two Real-T ...... A Detection and Quantification
@en
Differences between Two Real-T ...... A Detection and Quantification
@nl
P2093
P2860
P3181
P356
P1476
Differences between Two Real-T ...... A Detection and Quantification
@en
P2093
Annika Kau
Barbara C Gärtner
Christoph Sarrazin
Johannes Vermehren
Reinhild Göbel
P2860
P304
P3181
P356
10.1128/JCM.00755-08
P407
P577
2008-12-01T00:00:00Z